Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Plasma Cell Myeloma: early-phase trial registry
5 of 24 indexed Recurrent Plasma Cell Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 5 currently recruiting · #686 of 28,707 conditions by registered trial count
Recurrent Plasma Cell Myeloma: 24 US clinical trials tracked, 5 recruiting.
Recurrent Plasma Cell Myeloma is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 5 of these trials.
Enrollment posture brief
Registry condition recurrent-plasma-cell-myeloma
OPEN 5 | RECR 21% | LATE 0 | EARLY 21 | RANK #686 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Mobility Limitation (21% recruiting · 29 trials)
Recurrent Plasma Cell Myeloma lists 5 open slots (21% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Plasma Cell Myeloma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Plasma Cell Myeloma is recruiting below its size-band peers.
5 of 24 indexed trials (20.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Plasma Cell Myeloma research.
City of Hope Medical Center accounts for 5 of 24 trials (20.8%). 13 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Plasma Cell Myeloma trials plan to enrol fewer than 100 people.
Median target enrolment is 29 among the 24 trials that report a genuine target (sentinel values excluded). 20 of those (83.3%) plan for fewer than 100 participants.
-
Recurrent Plasma Cell Myeloma research is mostly interventional.
22 interventional and 2 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Roswell Park Cancer Institute
NCT05312255
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
NCT03017820
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
City of Hope Medical Center
NCT03710421
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
NCT04508790
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
City of Hope Medical Center
NCT05363111
Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers
M.D. Anderson Cancer Center
NCT04090619
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Academic and Community Cancer Research United
NCT04756401
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
NCT03763162
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Mayo Clinic
NCT04640779
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
NCT04205409
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
University of Southern California
NCT05514990
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
Emory University
NCT05391750
Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma
Mayo Clinic
NCT05411497
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
NCT04850599
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
SWOG Cancer Research Network
NCT01903811
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Emory University
NCT02765854
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
NCT01301807
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
National Cancer Institute (NCI)
NCT01711528
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
City of Hope Medical Center
NCT02119468
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
NCT03338972
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy
University of California, San Francisco
NCT04409314
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
City of Hope Medical Center
NCT01163357
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
OHSU Knight Cancer Institute
NCT02504359
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
Mayo Clinic
NCT03202628
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Plasma Cell Myeloma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Plasma Cell Myeloma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Plasma Cell Myeloma page
24 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Recurrent Plasma Cell Myeloma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- City of Hope Medical Center sponsors the most Recurrent Plasma Cell Myeloma trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Plasma Cell Myeloma condition card totals 24 registered trials; most-linked intervention Dexamethasone; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.